RecruitingNCT07048574
TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age
Sponsor
State University of New York at Buffalo
Enrollment
600 participants
Start Date
Jun 2, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This is a longitudinal, observational epidemiological study designed to estimate the prevalence of depression, anxiety, and behavior problems in children ages 18 months through 11 years with cystic fibrosis (CF).
Eligibility
Min Age: 18 MonthsMax Age: 11 Years
Plain Language Summary
Simplified for easier understanding
This study looks at how common depression, anxiety, and behavioral problems are in young children with cystic fibrosis (CF), a serious lung and digestive disease. Researchers will follow children over time to better understand these mental health challenges and how they change as kids grow.
**You may be eligible if:**
- Your child has been diagnosed with cystic fibrosis and is currently being followed by a CF care team at one of the participating sites
- Your child is between 18 months and 11 years old
- Your family speaks English or Spanish
- You (as a parent or guardian) are willing and able to give consent; children ages 7–11 will also be asked to agree to participate
**You may NOT be eligible if:**
- You or your child is unable or unwilling to complete study activities
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(13)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07048574
Related Trials
Phase 2 Study to Assess the Safety and Efficacy of ANG003
NCT0745054726 locations
Pharmacokinetics of Antibiotics in Patients With Cystic Fibrosis Trated With Elexacaftor/Tezacaftor/Ivacaftor (ETI)
NCT076299861 location
Ensuring Access to Optimal Therapy in CF: The ENACT Study
NCT071487393 locations
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
NCT070835571 location
Gastrointestinal Response of Pediatric Cystic Fibrosis Patients on Mediterranean Diet
NCT072232552 locations